Singapore Startup Raises $3M for Synthetic Skin Technology

Bioactivx, a Singapore-based medical technology startup, just raised $3 million to manufacture synthetic skin that helps chronic wounds finally heal.

The company spun off from Singapore's top research institutions, A*STAR and SingHealth, combining years of scientific expertise into a product called Bioactiv® Matrix. This synthetic material acts like temporary or permanent replacement skin, giving damaged tissue the support it needs to regenerate.

The funding round was co-led by Swiss family office ContInvest and Singapore venture firm Cocoon Capital. It brings Bioactivx's total funding to $4.9 million since launch.

The money will expand manufacturing facilities in Singapore, build out regulatory and commercial teams, and fund clinical trials after the product hits the market. Bioactivx is also developing additional treatments specifically for diabetic foot ulcers, which affect millions globally.

The company has already submitted its complete data package to Singapore's Health Sciences Authority for regulatory approval. If approved, Singapore will be among the first markets to access the technology in late 2026, with regional expansion planned for 2027.

The Ripple Effect

Diabetic foot ulcers represent more than just painful wounds. They carry devastating treatment costs and significant amputation risk for patients worldwide. Advanced wound care technologies like Bioactiv® Matrix could transform outcomes for people who've run out of healing options with traditional treatments.

Singapore continues proving itself as a global hub for medical innovation. When research institutions like A*STAR partner with hospitals like SingHealth, they create pathways for laboratory discoveries to reach patients who need them most.

The $3 million investment may seem modest compared to blockbuster tech deals, but it reflects growing confidence in early-stage medical technology. Investors recognize that solving real health problems creates both humanitarian and financial returns.

For the estimated 18.6 million people living with diabetic foot ulcers globally, technologies emerging from Singapore's research labs represent genuine hope for healing.